ArticleBlood2010
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 158 citations in OpenAlex.
- Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma.International journal of hematology · 2017Trial
- Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.Haematologica · 2013Trial
- Responses to Nei-Xiao-Luo-Li-San in Toledo Diffuse Large B-Cell Lymphoma Cells: Potential Involvement of ATF5- and HDAC-Associated Epigenetic Changes.Biomedicines · 2026Article
- High-Dimensional Vitreous Proteomics Identifies Epigenetic Pathway Signatures in Vitreoretinal Lymphoma.Ophthalmology science · 2026Article
- DNA methylation-based classification of hematolymphoid neoplasms.Blood advances · 2026Article
- Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.Blood advances · 2026Article
- Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.Annals of hematology · 2026Article
- DNA Hypermethylation of the ZNF382 Promoter Region and Low mRNA Expression of ZNF382 Promote Diffuse Large B-Cell Lymphoma Occurrence and Progression.Cancer reports (Hoboken, N.J.) · 2026Article
- Integration of high-throughput proteomic data and complementary omics layers with PriOmics.Genome research · 2026Article
- A multi-omics integrative analyses revealsFrontiers in pharmacology · 2026Article
- HIV-associated non-Hodgkin lymphoma tumor-microenvironment axes differ by EBV status across cellular origins.bioRxiv : the preprint server for biology · 2025Article
- The EBV-Positive Tumor Methylome Is Distinct from EBV-Negative in Diffuse Large B-Cell Lymphoma.Cancers · 2025Article
- Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma.Nature communications · 2025Article
- Interaction between stromal cells and tumor cells promotes GCB-DLBCL cell survival via the CD40/RANK-KDM6B-NF-κB axis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients.International journal of molecular sciences · 2024Article
- The prognostic value of hydroxybutyrate dehydrogenase in diffuse large B cell lymphoma.iScience · 2024Article
- Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.Clinical epigenetics · 2024Article
- Arsenic disulfide promoted the demethylation ofPeerJ · 2024Article
- EpiMix is an integrative tool for epigenomic subtyping using DNA methylation.Cell reports methods · 2023Article
- Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis.Nature communications · 2023Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Expression profiling has shown 2 main and clinically distinct subtypes of diffuse large B-cell lymphomas (DLBCLs): germinal-center B cell-like (GCB) and activated B cell-like (ABC) DLBCLs. Further work has shown that these subtypes are partially characterized by distinct genetic alterations and different survival. Here, we show with the use of an assay that measures DNA methylation levels of 50,000 CpG motifs distributed among more than 14,000 promoters that these 2 DLBCL subtypes are also characterized by distinct epigenetic profiles. DNA methylation and gene expression profiling were performed on a cohort of 69 patients with DLBCL. After assigning ABC or GCB labels with a Bayesian expression classifier trained on an independent dataset, a supervised analysis identified 311 differentially methylated probe sets (263 unique genes) between ABC and GCB DLBCLs. Integrated analysis of methylation and gene expression showed a core tumor necrosis factor-α signaling pathway as the principal differentially perturbed gene network. Sixteen genes overlapped between the core ABC/GCB methylation and expression signatures and encoded important proteins such as IKZF1. This reduced gene set was an accurate predictor of ABC and GCB subtypes. Collectively, the data suggest that epigenetic patterning contributes to the ABC and GCB DLBCL phenotypes and could serve as useful biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.